Association study between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and metabolic syndrome

Table 2 Prevalence (%) of metabolic syndrome components according to the SST poly-T repeat polymorphism genotype

	Genotypes
All subjects	13/13	13/14	13/15	13/16	p
n	913	69	571	172
Abdominal Obesity	58.3	65.2	59.5	69.8	0.032
Hypertriglyceridemia	50.4	55.1	55.7	61.6	0.026
Low HDL-C level	51.2	50.7	51.5	62.2	0.058
Hypertension	33.6	23.2	39.2	42.4	0.005
Hyperglycaemia	36.5	46.4	38.2	45.9	0.060
Diagnosis of Metabolic Syndrome	46.8	47.8	49.6	61.6	0.005
Men
n	475	38	289	99
Abdominal Obesity	74.5	73.7	72.3	80.8	NS
Hypertriglyceridemia	53.3	63.2	60.2	68.7	0.019
Low HDL-C level	55.6	50.0	56.4	67.7	NS
Hypertension	33.3	21.1	34.6	35.4	NS
Hyperglycaemia	43.6	55.3	42.9	49.5	NS
Diagnosis of Metabolic Syndrome	57.1	52.6	56.7	66.7	NS
Women
n	438	31	282	73
Abdominal Obesity	40.6	54.8	46.5	54.8	0.056
Hypertriglyceridemia	47.3	45.2	51.1	52.1	NS
Low HDL-C level	46.3	51.6	46.5	54.8	NS
Hypertension	34.0	25.8	44.0	52.1	0.002
Hyperglycaemia	28.8	35.5	33.3	41.1	NS
Diagnosis of Metabolic Syndrome	35.6	41.9	42.2	54.8	0.013

NS: p ≥ 0.1 Abdominal obesity = waist circumference > 102 cm in men or > 88 cm in women; Hypertriglyceridemia = TG > 1.7 mmol/L; Low HDL-C level = HDL-Cholesterol < 1.03 mmol/L in men or < 1.3 mmol/L in women; Hypertension = blood pressure ≥ 130 mmHg systolic blood pressure or ≥ 85 mmHg diastolic blood pressure or hypertensive treatment; Hyperglycaemia = fasting glucose > 5.6 mmol/L or drug treatment for elevated blood glucose
Significant p-value are in bold

ISSN: 1471-2350